Haixiang Pharmaceutical and Wanbangde Pharmaceutical signed an innovative drug cooperation agreement focusing on the research and development of orphan drugs for ALS.
January 13, 2026
Source: drugdu
31
Haixiang Pharmaceutical(002099) issued an announcement stating that on January 12, 2026, the company and Wanbangde...Wanbangde Pharmaceutical Group Co., Ltd., a wholly-owned subsidiary of Pharmaceutical Holdings Group Co., Ltd. (002082), signed an " Innovative Drug..."The two parties will collaborate on the indication of ALS (Amyotrophic Lateral Sclerosis), initially focusing on the research and commercialization of WP205, a product of Wanbangde Pharmaceuticals that has already received orphan drug designation.
The agreement stipulates that Haixiang Pharmaceutical will provide a total of RMB 150 million in funding, and 15% of the cooperation profits will be distributed to Haixiang Pharmaceutical . The agreement will take effect after being reviewed and approved by the shareholders' meeting of Wanbangde Pharmaceutical Holdings Group Co., Ltd.
In the first three quarters of 2025, Haixiang Pharmaceutical achieved revenue of 1.367 billion yuan and net profit attributable to the parent company of 7.29 million yuan.
https://finance.eastmoney.com/a/202601123615957442.html
By editor
Copyright©2026 Ddu. All rights reserved.
Read more on
- NVIDIA and Eli Lilly jointly invested 1 billion US dollars to establish an AI drug research laboratory January 13, 2026
- 3D Medicines’ innovative drug Envita has been accepted by the National Medical Products Administration for marketing approval for first-line treatment of biliary tract cancer. January 13, 2026
- China’s dual-resistance technology is on a roll! Rongchang RC148 secures a $5.6 billion order from AbbVie January 13, 2026
- The marketing application of CSPC Pharmaceutical Group’s pulgliptin metformin extended-release tablets has been accepted by the National Medical Products Administration. January 13, 2026
- Despite a failure rate exceeding 50%, Shandong Zhitai successfully broke through and obtained the first generic drug approval. January 13, 2026
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
